As per Fucikova et al., although a higher tumor mutational burden (TMB) and significant CD8+ T-cell infiltration have been associated with improved outcomes in EOC patients undergoing conventional chemotherapy, this correlation does not apply to female patients undergoing DCVAC treatment. The gene discussed is CD8A; the disease is neoplasm.